Skip to main content
. 2018 Jun 1;10(5):796–802. doi: 10.1080/19420862.2018.1457599

Figure 2.

Figure 2.

Fasting and Fed Plasma Glucose and Plasma Insulin. (A) Fasting plasma glucose (in mg/dL) in wild-type mice treated with control antibody (n = 10), wild-type mice treated with XMetD (n = 10), SUR-1 −/− mice treated with control antibody (n = 10), SUR-1 −/− mice treated with XMetD (n = 10). * P≤0.001: wild-type vs. SUR-1 −/−; # P≤0.005 SUR-1 −/− control vs. SUR-1 −/− XMetD. (B) Fed plasma glucose (in mg/dL) in wild-type mice treated with control antibody (n = 10), wild-type mice treated with XMetD (n = 10), SUR-1 −/− mice treated with control antibody (n = 10), SUR-1 −/− mice treated with XMetD (n = 10). * P≤0.05: wild-type vs. SUR-1 −/−; # P≤0.01 SUR-1 −/− control vs. SUR-1 −/− XMetD; ^ P≤0.03 wild-type control vs. wild-type XMetD (C) Fasting plasma insulin levels (in ng/mL) in wild-type mice treated with control antibody (n = 10), wild-type mice treated with XMetD (n = 10), SUR-1 −/− mice treated with control antibody (n = 10), SUR-1 −/− mice treated with XMetD (n = 10). # P≤0.0004 SUR-1 −/− control vs. SUR-1 −/− XMetD; ^ P≤0.0004 wild-type control vs. wild-type XMetD.